Form PTO-1449 (Modified)	Atty. Docket No. 30744/6248.10	Serial No. 10/669,611
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	Applicants Wong et al.	
	Filing Date September 24, 2003	Art Unit 1614

PTO/SB/08A (10-01)
AUG 30 2004
PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Issue or Publication Date	Name	Class	Sub class	Filing Date (If Appropriate)
PS	6,290,986	09/18/2001	Murdock et al.	424	449	06/29/1998
PS	6,479,074	11/12/2002	Murdock et al.	424	449	06/29/1998
PS	6,572,880	06/03/2003	Murdock et al.	424	449	01/03/2001

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Publication Date	Country	Translation Yes	Translation No
PS	WO 00/00120	01/06/2000	PCT		
PS	WO 01/62236	08/30/2001	PCT		
PS	WO 99/11208	03/11/1999	PCT		

Examiner Initials	OTHER DOCUMENTS (Author, Title, Journal, Volume, Pages, and Date)
PS	Mucci, M., "Reboxetine: A Review of Antidepressant Tolerability," *Journal of Psychopharmacology, Oxford University Press*, 11(4):533-537 Supp, 1997.
	~~Search Report in counterpart EP 04013383.7-2123, dated July 22, 2004 (4 pages).~~

EXAMINER: Phyllis Spivack	DATE CONSIDERED: 9/5/05

Form PTO-1449 (Modified)	Atty. Docket No. 30744/6248.10	Serial No. 10/669,611
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	Applicants Wong et al.	
	Filing Date September 24, 2003	Art Unit 1614

OIPE SEP 10 2004 PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Issue or Publication Date	Name	Class	Sub class	Filing Date (If Appropriate)

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Publication Date	Country	Translation Yes	Translation No
PS	WO 01/47503	07/05/2001	PCT		

Examiner Initials	OTHER DOCUMENTS (Author, Title, Journal, Volume, Pages, and Date)
	~~Search Report in counterpart EP 04013382.9-2123, dated July 22, 2004~~ (4 pages).

EXAMINER: Phyllis Spivack	DATE CONSIDERED: 9/5/05

Form PTO-1449 (Modified)	Atty. Docket No. 28341/6248.10	Serial No. 10/666,911
INFORMATION DISCLOSURE STATEMENT	Applicant(s) Erik H.F. Wong et al.	
	Filing Date September 24, 2003	Art Unit 1614

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Issue or Publication Date	Name	Class	Subclass	Filing Date (If Appropriate)
PS	4,229,449	10-21-1980	Melloni et al.	424	248.58	
PS	4,596,807	06-24-1986	Crosby	514	277	
PS	5,068,433	11-26-1991	Melloni et al.	564	349	
PS	5,192,751	03-09-1993	Thor	514	82	
PS	5,281,624	01-25-1994	Gehlert et al.	514	651	
PS	5,391,735	02-21-1995	Melloni et al.	544	174	
PS	5,441,985	08-15-1995	Foreman	514	357	
PS	5,744,474	04-28-1998	Thor	514	357	
PS	5,922,914	07-13-1999	Gage et al.	564	413	
PS	5,998,430	12-07-1999	Schwantes et al.	514	299	
PS	6,028,070	02-22-2000	Heiligenstein	514	238.8	
PS	6,046,193	04-04-2000	Heiligenstein	514	239.2	
PS	6,066,643	05-23-2000	Perry	514	269	
PS	6,465,458	10-15-2002	Wong et al.	514	239.2	
PS	6,610,690	08-26-2003	Wong et al.	514	239.2	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Publication Date	Country	Translation Yes	Translation No
PS	2,014,981	09-05-1979	United Kingdom		
PS	2,167,407	05-11-1988	United Kingdom		
PS	WO 96.12485	05-02-1996	PCT		
PS	WO 97/35584	10-02-1997	PCT		

EXAMINER: Phyllis Spivack	DATE CONSIDERED: 9/5/05

Form PTO-1449 (Modified)	Atty. Docket No. 28341/6248.10	Serial No. 10/669,611
INFORMATION DISCLOSURE STATEMENT	Applicant(s) Erik H.F. Wong et al.	
	Filing Date September 24, 2003	Art Unit 1614

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Publication Date	Country	Translation Yes	Translation No
PS	WO 97/35586	10-02-1997	PCT		
PS	WO 99/15163	04-01-1999	PCT		
PS	WO 99/15176	04-01-1999	PCT		
PS	WO 99/15177	04-01-1999	PCT		
PS	WO 99/20279	04-29-1999	PCT		
PS	WO 99/52531	10-21-1999	PCT		
PS	WO 99/52518	10-21-1999	PCT		
PS	WO 99/58130	11-18-1999	PCT		

OTHER DOCUMENTS

PS	J.J. Schildkraut, The Catecholamine Hypothesis of Affective Disorders: A Review of Supporting Evidence. Am. J. Psychiatry, Vol. 122, pp. 509-22 (Nov. 1965).
PS	T.H. Svensson, et al., Feedback Inhibition of Brain Noradrenaline Neurons by Tricyclic Antidepressants: a-Receptor Mediation, Science, Vol. 202, pp. 1089-91 (1984).
PS	E. Richelson et al., Blockade by Antidepressants and Related Compounds of Biogenic Amine Uptake into Rat Brain Synaptosomes: Most Antidepressants Selectively Block
PS	C.B. Nemeroff, The Neurobiology of Depression, Scientific American (1988) (8 pages).
PS	M. Riva et al., Effect of Reboxetine, A New Antidepressant Drug, on the Central Noradrenergic System: Behavioral and Biochemical Studies, J. Drug Dev., Vol. 1, no. 4 (1988)
PS	T. Pacholczyk et al., Expression Cloning of a Cocaine-and Antidepressant-Sensitive Human Noradrenaline Transporter, Nature, Vol. 350, no. 28, pp. 350-56 (March 1991).
PS	M. Max et al., Efficacy of Desipramine in Painful Diabetic Neuropathy: A Placebo-Controlled Trial, Pain, Vol. 45, pp. 3-9 (1991).
PS	E. Richelson, Biological Basis of Depression and Therapeutic Relevance, J. Clin. Psychiatry, Vol. 52, no. 6 Suppl., pp. 4-10 (June 1991).
PS	M. Max et al., Effects of Desipramine Amitriptyline and Fluoxetine on Pain in Diabetic Neuropathy, New Engl. J. Med., Vol. 326, No. 19, pp. 1250-56 (1992).
PS	B. Cusack et al., Binding Antidepressants to Human Brain Receptors: Focus on Newer Generation Compounds, Psychopharmacology, Vol. 114, pp. 559-65 (1994).
PS	M. Max, "Treatment of Post-Herpetic Neuralgia: Antidepressants," Ann. Neurol., Vol. 35, Suppl., pp. s50-s53 (1994).

EXAMINER: Phyllis Spivack	DATE CONSIDERED: 9/5/05

Form PTO-1449 (Modified)	Atty. Docket No. 28341/6248.10	Serial No. 10/669611
INFORMATION DISCLOSURE STATEMENT	Applicant(s) Erik H.F. Wong et al.	
	Filing Date September 24, 2003	Art Unit

PS	W. Reimann et al., "Inhibition of Spinal Noradrenaline Uptake in Rats by the Centrally Acting Analgesic Tramadol," Biochem. Pharmacol., Vol. 47, No. 12, pp. 2289-93 (1994).
PS	C. Pellizzoni et al., Pharmacokinetics of Reboxetine in Healthy Volunteers, Single Against Repeated Oral Doses and lack of Enzymatic Alterations, Biopharm. Drug Dispos., Vol.
PS	R.J. Baldessarini, Depression and Mania, Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., Chapter 19, pp. 431-39, (1996).
PS	B.E. Leonard, Noradrenaline in Basic Models of Depression, European Neuropsychopharmacology, Vol. 7, Suppl. 1, pp. S11-S16 (1997).
PS	Discussion, European Neuropsychopharmacology, Vol. 7, Suppl. 1, pp.S71-S73 (1997).
PS	S.A. Montgomery, Is There a Role for a Pure Noradrenergic Drug in the Treatment of Depression?, Eur. Neuropsychopharmacology, Vol. 7, Suppl. 1, pp. S3-S9 (1997).
PS	S.A. Montgomery, Reboxetine: Additional Benefits to the Depressed Pateint, J. Psychopharmacology (Oxf), 11:4 Abstract (1997).
PS	I. Hindmarch, The Effects of Antidepressants on Psychomotor Function with Particular Reference to Reboxetine, Eur. Neuropsychopharmacology, Vol. 7, Suppl. 1, pp. S17-S21
PS	E. Frigerio et al., Pharmacokinetics of Reboxetine Enantimoers in the Dog, Chirality, Vol. 9, pp. 303-06 (1997).
PS	A. Frazer, Pharmacology of Antidepressants, J. Clinical Psychopharmacology, Vol. 17, no. 2, Suppl. 1, pp. 2S-18S (1997).
PS	B.E. Leonard, The Role of Noradrenaline in Depression: A Review, J. Psychopharmacology, Vol. II, No. 4, Suppl. pp. S39-S47 (1997).
PS	Dostert et al., Review of the Pharmacokinetics and Metabolism of Reboxetine, A Selective Noradrenaline Reuptake Inhibitor," Euro. Neuropsychopharmacol., Vol. 7, Suppl. 1, pp.
PS	M. Owens et al., "Neurotransmitter Receptor and Transporter Binding Profile of Antidepressants and Their Metabolites," J. Pharmacol. Exp. Ther., Vol. 283, pp. 1305-
PS	D. Healy et al., The Clinical Pharmacologic Profile of Reboxetine: Does it Involve the Putative Neurobiological Substrate of Wellbeing?, J. of Affective Disorders, Vol. 1, pp.
PS	Anonymous, Reboxetine - Another New Antidepressant, Drugs and Therapeutics Bull., 36 (11) (1998).
PS	S.A. Montgomery, The Place of Reboxetine in Antidepressant Therapy, J. of Clinical Psychiatry, Vol. 59, Suppl. 14, pp. 26-29 (1998).
PS	G.D. Burrows et al., Antidepressant Efficacy and Tolerability of the Selective Norepinephrine Reuptake Inhibitor Reboxetine: A Review, J. Clin. Psychiatry, Vol. 59, Suppl. 14, 1998.
PS	J. Massana, Reboxetine Versus Fluoxetine: An Overview of Efficacy and Tolerability, J. Clin. Psychiatry, Vol. 59, Suppl. 14, pp. 8-10 (1998).
PS	A. Harkin et al., Activity and Onset of Action of Reboxetine and Effect of Combination with Sertraline in an Animal Model of Depression, Eur. J. of Pharmacology, pp. 1-10 (1998).
PS	J. Massana et al., Reboxetine: A Double-Blind Comparison with Fluoxetine in Major Depressive Disorder, Int. Clin. Psychopharmacol, Vol. 14, No. 2, pp.73-80 (1999).
PS	J.C. Fleishaker et al., Absolute Bioavailability of Reboxetine Enantiomers and Effect of Gender on Pharmacokinetics, Biopharm. Drug Dispos. Vol. 20, No. 1, pp.53-57 (1999).
PS	K. Moore et al., "Tissue Distribution of Tramadol and Metabolites in an Overdose Fatality," Am. J. of Forensic Med. and Path., Vol. 20, No. 1, pp. 98-100 (1999).
PS	S. Kasper, From Symptoms to Social Functioning: Differential Effects of Antidepressant Therapy, International Clinical Psychopharmacology, Vol. 14, Suppl. 1, pp. S27-S31, 1999.

EXAMINER: Phyllis Spivack	DATE CONSIDERED: 9/5/05

Form PTO-1449 (Modified)	Atty. Docket No. 28341/6248.10	Serial No. 10/669,611
INFORMATION DISCLOSURE STATEMENT	Applicant(s) Erik H.F. Wong et al.	
	Filing Date September 24, 2003	Art Unit

	International Search Report in PCT/US00/17256 dated July 12, 2001.
	International Preliminary Examination Report in PCT/US00/17256 dated December 19, 2001.
	"Notice of Allowance and Fee(s) Due" dated March 25, 2003, sent by the United States Patent and Trademark Office for U.S. Serial No. 10/037,344 (4 pages).

EXAMINER:	DATE CONSIDERED: